$CLRB
Cellectar Biosciences, Inc.

2022 Q4 Form 10-Q Financial Statement

#000141057822002920 Filed on November 03, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.969M $2.435M
YoY Change 28.24% 29.39%
% of Gross Profit
Research & Development $5.454M $5.380M
YoY Change 24.28% 36.64%
% of Gross Profit
Depreciation & Amortization $38.16K $32.96K
YoY Change -2.9% -10.39%
% of Gross Profit
Operating Expenses $7.423M $5.380M
YoY Change 25.31% 36.64%
Operating Profit -$7.815M
YoY Change 34.29%
Interest Expense $147.4K $4.164K
YoY Change -11185.71% 605.76%
% of Operating Profit
Other Income/Expense, Net $4.164K
YoY Change 605.76%
Pretax Income -$7.275M -$7.811M
YoY Change 22.93% 34.24%
Income Tax -$60.00K
% Of Pretax Income
Net Earnings -$7.215M -$7.811M
YoY Change 21.92% 34.24%
Net Earnings / Revenue
Basic Earnings Per Share -$1.28
Diluted Earnings Per Share -$0.73 -$1.28
COMMON SHARES
Basic Shares Outstanding 9.385M 6.110M
Diluted Shares Outstanding 6.110M

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $19.87M $17.79M
YoY Change -44.36% -55.92%
Cash & Equivalents $19.87M $17.79M
Short-Term Investments
Other Short-Term Assets $663.2K $975.9K
YoY Change -23.54% -6.88%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $20.53M $18.76M
YoY Change -43.86% -54.68%
LONG-TERM ASSETS
Property, Plant & Equipment $418.6K $338.9K
YoY Change 21.52% 33.42%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $6.214K $81.21K
YoY Change 0.0% 1206.89%
Total Long-Term Assets $1.060M $558.3K
YoY Change 68.19% -0.39%
TOTAL ASSETS
Total Short-Term Assets $20.53M $18.76M
Total Long-Term Assets $1.060M $558.3K
Total Assets $21.59M $19.32M
YoY Change -41.97% -53.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.558M $6.367M
YoY Change 80.78% 109.82%
Accrued Expenses $50.85K $148.2K
YoY Change -62.46% 12.78%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.529M $6.515M
YoY Change 38.57% 105.79%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $553.0K $53.77K
YoY Change 232.54% -73.38%
Total Long-Term Liabilities $553.0K $53.77K
YoY Change 232.54% -73.38%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.529M $6.515M
Total Long-Term Liabilities $553.0K $53.77K
Total Liabilities $6.082M $6.569M
YoY Change 46.33% 95.05%
SHAREHOLDERS EQUITY
Retained Earnings -$179.5M -$172.3M
YoY Change 18.95% 18.83%
Common Stock $94.00 $61.00
YoY Change 54.1% -90.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $15.51M $12.75M
YoY Change
Total Liabilities & Shareholders Equity $21.59M $19.32M
YoY Change -41.97% -53.95%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income -$7.215M -$7.811M
YoY Change 21.92% 34.24%
Depreciation, Depletion And Amortization $38.16K $32.96K
YoY Change -2.9% -10.39%
Cash From Operating Activities -$7.412M -$7.013M
YoY Change 64.3% 9.09%
INVESTING ACTIVITIES
Capital Expenditures $117.9K -$7.070K
YoY Change -190.84% 74.14%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$117.9K -$7.070K
YoY Change -9.16% 74.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.611M 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -7.412M -7.013M
Cash From Investing Activities -117.9K -7.070K
Cash From Financing Activities 9.611M 0.000
Net Change In Cash 2.081M -7.020M
YoY Change -144.84% 9.13%
FREE CASH FLOW
Cash From Operating Activities -$7.412M -$7.013M
Capital Expenditures $117.9K -$7.070K
Free Cash Flow -$7.530M -$7.006M
YoY Change 71.86% 9.04%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei City Area Code
CityAreaCode
608
dei Local Phone Number
LocalPhoneNumber
441-8120
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
20.41
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
6.14
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
42.40
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
9.20
CY2022Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.10
dei Security12b Title
Security12bTitle
Common stock, par value $0.00001
dei Trading Symbol
TradingSymbol
CLRB
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.28
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.97
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.50
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.39
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6110119
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5986837
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6110123
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5363342
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Central Index Key
EntityCentralIndexKey
0001279704
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Entity Registrant Name
EntityRegistrantName
Cellectar Biosciences, Inc.
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-172283951
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
111
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
111
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6110125
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6110119
us-gaap Net Income Loss
NetIncomeLoss
-21386162
CY2022Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.10
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
1-36598
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-3321804
dei Entity Address Address Line1
EntityAddressAddressLine1
100 Campus Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Florham Park
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07932
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
9385272
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17785322
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35703975
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
975936
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
867485
CY2022Q3 us-gaap Assets Current
AssetsCurrent
18761258
CY2021Q4 us-gaap Assets Current
AssetsCurrent
36571460
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
338944
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
344491
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
138097
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
204644
CY2022Q3 us-gaap Investments And Other Noncurrent Assets
InvestmentsAndOtherNoncurrentAssets
81214
CY2021Q4 us-gaap Investments And Other Noncurrent Assets
InvestmentsAndOtherNoncurrentAssets
81214
CY2022Q3 us-gaap Assets
Assets
19319513
CY2021Q4 us-gaap Assets
Assets
37201809
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6367035
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3854914
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
148200
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
135449
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
6515235
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3990363
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
53769
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
166292
CY2022Q3 us-gaap Liabilities
Liabilities
6569004
CY2021Q4 us-gaap Liabilities
Liabilities
4156655
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
111
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
111
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
1382023
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
1382023
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6110119
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6110125
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
61
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
61
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
183652376
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
182560859
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-172283951
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-150897789
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
12750509
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
33045154
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19319513
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
37201809
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5380190
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3937464
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13765846
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13198294
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2435296
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1882190
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7625391
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5009581
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
7815486
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
5819654
us-gaap Costs And Expenses
CostsAndExpenses
21391237
us-gaap Costs And Expenses
CostsAndExpenses
18207875
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7815486
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5819654
us-gaap Operating Income Loss
OperatingIncomeLoss
-21391237
us-gaap Operating Income Loss
OperatingIncomeLoss
-18207875
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
4164
CY2021Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
590
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
5075
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3611
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4164
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
590
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5075
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3611
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7811322
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-5819064
us-gaap Net Income Loss
NetIncomeLoss
-21386162
us-gaap Net Income Loss
NetIncomeLoss
-18204264
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.28
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.97
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.50
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.39
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6110119
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5986837
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6110123
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5363342
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
54794529
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
124564
CY2021Q1 clrb Stock Issued During Period On Exercise Of Warrants Value
StockIssuedDuringPeriodOnExerciseOfWarrantsValue
1213924
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-6357170
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
49775847
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
200617
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
34873
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-6028030
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
43983307
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
421161
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-5819064
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
38585404
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
33045154
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
303805
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-6139797
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
27209162
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
419953
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-7435043
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
20194072
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
367759
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7811322
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
12750509
us-gaap Net Income Loss
NetIncomeLoss
-21386162
us-gaap Net Income Loss
NetIncomeLoss
-18204264
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
110276
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
110624
us-gaap Share Based Compensation
ShareBasedCompensation
1091517
us-gaap Share Based Compensation
ShareBasedCompensation
746342
clrb Non Cash Lease Expense
NonCashLeaseExpense
66547
clrb Non Cash Lease Expense
NonCashLeaseExpense
57160
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-3386
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-2938
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
108451
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
273650
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-99772
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-88268
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2512121
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-408708
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17810538
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18057826
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
108115
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11622
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-108115
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11622
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
34874
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
1213924
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1248798
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-17918653
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-16820650
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35703975
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57165377
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17785322
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40344727
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
18653826
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2144000
clrb Employee Service Share Based Compensation Nonvested Total Compensation In Current Year
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInCurrentYear
366000
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
340250
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
353750
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Concentration of Credit Risk</span> — Financial instruments that subject the Company to credit risk consist of cash and cash equivalents on deposit with financial institutions. The Company’s excess cash as of September 30, 2022 and December 31, 2021 is on deposit in interest-bearing accounts with well-established financial institutions. At times, such amounts may exceed the FDIC insurance limits. As of September 30, 2022 and December 31, 2021, uninsured cash balances totaled approximately $17,300,000 and $35,200,000, respectively.</p>
CY2022Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
17300000
CY2021Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
35200000
clrb Employee Service Share Based Compensation Nonvested Total Compensation In Year Two
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInYearTwo
1244900
clrb Employee Service Share Based Compensation Nonvested Total Compensation In Year Three
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInYearThree
501100
clrb Employee Service Share Based Compensation Nonvested Total Compensation In Year Four
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInYearFour
32000
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2021 clrb Preferred Stock Convertible Beneficial Conversion Feature
PreferredStockConvertibleBeneficialConversionFeature
0
CY2022Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1563381
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
281000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
17.40
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2328755
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2772583
CY2018Q4 clrb Deferred Lease Liability
DeferredLeaseLiability
176000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
202000
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.10
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
40000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
161000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
14000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
215000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
13000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
202000

Files In Submission

Name View Source Status
0001410578-22-002920-index-headers.html Edgar Link pending
0001410578-22-002920-index.html Edgar Link pending
0001410578-22-002920.txt Edgar Link pending
0001410578-22-002920-xbrl.zip Edgar Link pending
clrb-20220930.xsd Edgar Link pending
clrb-20220930x10q.htm Edgar Link pending
clrb-20220930xex31d1.htm Edgar Link pending
clrb-20220930xex31d2.htm Edgar Link pending
clrb-20220930xex32d1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
clrb-20220930_cal.xml Edgar Link unprocessable
clrb-20220930_def.xml Edgar Link unprocessable
clrb-20220930_pre.xml Edgar Link unprocessable
clrb-20220930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
clrb-20220930x10q_htm.xml Edgar Link completed